Read the Rule Changes Before They Change Your Business

The FDA and the medical device industry reached an agreement in principle on MDUFA VI in March, the user-fee framework that will govern device submissions through 2032, with the formal commitment letter being drafted now and the package heading to Congress by January 15, 2027, per MedTech Dive and RAPS. The operational changes inside the agreement are real and specific. A new “not grantable” De Novo decision option will give applicants a second pass before a formal decline. Pre-sub fees are being raised but now convert into credits toward future marketing submissions. TAP 2.0 is launching as the next Total Product Life Cycle Advisory Program. Seven priority expansion areas are codified, including real-world evidence, digital infrastructure, and global alignment. Fiscal 2028 fees will fall for most US firms while foreign manufacturers absorb a higher establishment fee under an “America-First” split. None of this looks like a headline that demands attention on a Tuesday morning. All of it changes how a regulated hardware company has to think about its capital plan, its team, and its operating cadence for the next five years. Understanding the market is only part of the job. Making money, building systems, and getting to where you want to go, those are the problems The Build exists to help you think through, and the structural rule changes that quietly rewrite how a business has to operate are exactly the kind of thing a monthly print issue is built to cover at the depth they require.

Rule Changes Are the Cheapest Edge Most Founders Refuse to Take

The default first-time founder treats regulatory and policy changes as background noise that someone else on the team will summarize at the right moment. The CEO reads the headline, the head of regulatory absorbs the detail, the rest of the company keeps moving against the operating plan that was written before the change landed. The pattern is understandable. The detail underneath a change like MDUFA VI is technical, slow-moving, and not obviously connected to the next milestone on the deck. It is also where the asymmetric advantages get distributed. A founder who reads the commitment letter the week it lands publicly, understands which clauses change the company’s capital plan, and reshapes the regulatory and operating program against the new rules within thirty days is operating at a different cadence than the company that absorbs the change after the next round closes and discovers, halfway through the use of proceeds, that the assumptions no longer hold. The cost of the slower posture is a fundraising round priced against rules that have already moved. The cost of the faster posture is two weeks of focused reading and a couple of working sessions with the senior team.

The version of the business that compounds through environments like this is the one whose founder treats rule changes as a structural input on the same level as a customer signal or a competitor move. That means the policy and regulatory layer of the business has a dedicated cadence inside the operating rhythm, not an ad-hoc carve-out. It means the capital plan is sensitized to the realistic distribution of outcomes the new rules produce, not anchored on the cleanest version of the path. It means the team architecture is designed so that when a rule changes, there is a clear owner whose job is to translate the change into specific operational consequences for engineering, regulatory, manufacturing, finance, and the board, with a date by which the translation has to be done. The mechanics are unglamorous. The compounding advantage is real. A company that runs that cadence quarter after quarter ends up at a different place than the one whose founders thought policy was an external constraint to be reacted to rather than a structural input to be designed around.

The same logic applies to every category of regulated or capital-intensive hardware. The CMS-FDA RAPID pathway in MedTech is a rule change. The DAWG reorganization in defense procurement is a rule change. The Inflation Reduction Act tax-credit transferability rules in climate hardware are a rule change. The Pentagon’s Deal Team Six standing up to rewrite contractor scoring is a rule change. Each of those landed publicly with a quiet release schedule and rewrote the economics for the founders who read them carefully. MDUFA VI is the next one in line, and the founders who read it cleanly in the May-through-December 2026 window will spend 2027 and 2028 operating against a clearer picture of how the agency is going to behave than the founders who absorb the rules after the round closes.

Three Mechanics Worth Studying

The first mechanic is the “not grantable” letter on De Novo. The agency is introducing a third decision option that gives the applicant a second pass before a formal decline, structurally identical to the “not approvable” mechanism on PMA, per RAPS. The operational effect is to convert the binary outcome of a De Novo submission into a probabilistic distribution with three landing zones rather than two. A founder who designs the pre-submission program against the new distribution arrives at the decision point holding a second-pass plan already drafted. A founder who designs against the old binary arrives holding a press release and a fundraising plan that assumed the press release would be the headline.

The second mechanic is the pre-sub fee converting into a credit toward a future marketing submission, with Breakthrough and STeP devices exempt, per RAPS. The structural effect is to penalize the historical pattern of running an inflated number of unfocused pre-sub interactions while preserving the program for companies that arrive with sharp, well-formed questions. For founders, the read is that the regulatory program now has a built-in incentive to think in concrete artifacts rather than open-ended discussions. The team that uses pre-subs as expensive office hours burns the credit and weakens the package. The team that uses them as focused, documented decision points banks the credit and strengthens it.

The third mechanic is the TAP 2.0 program and the seven priority expansion areas, which formally include real-world evidence, consensus standards, global alignment, digital infrastructure, digital health, and patient science, per MedTech Dive. The structural effect is that the agency has publicly committed to building working frameworks in each of those areas over the next five years. A company that engages TAP 2.0 with a concrete real-world-evidence proposal or a digital-health architecture question is engaging the door the agency has just opened. A company that waits for someone else to figure out what those frameworks look like in practice will spend the next regulatory cycle reacting to other people’s precedents rather than setting its own.